{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:36:20Z","timestamp":1774866980284,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T00:00:00Z","timestamp":1243296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00702-009-0242-9","type":"journal-article","created":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T14:38:53Z","timestamp":1243262333000},"page":"867-874","source":"Crossref","is-referenced-by-count":7,"title":["Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats"],"prefix":"10.1007","volume":"116","author":[{"given":"Virgili","family":"P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Sosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Barbanoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignasi","family":"Gich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Rodr\u00edguez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,26]]},"reference":[{"key":"242_CR1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0006-8993(90)91318-B","volume":"525","author":"ED Abercrombie","year":"1990","unstructured":"Abercrombie ED, Bonatz AE, Zigmond MJ (1990) Effects of l-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 525:36\u201344","journal-title":"Brain Res"},{"key":"242_CR2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448\u2013458","journal-title":"Mov Disord"},{"key":"242_CR3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1469-7580.2000.19640587.x","volume":"196","author":"GW Arbuthnott","year":"2000","unstructured":"Arbuthnott GW, Ingham CA, Wickens JR (2000) Dopamine and synaptic plasticity in the neostriatum. J Anat 196:587\u2013596","journal-title":"J Anat"},{"key":"242_CR4","doi-asserted-by":"crossref","first-page":"9595","DOI":"10.1523\/JNEUROSCI.2583-07.2007","volume":"27","author":"P Belujon","year":"2007","unstructured":"Belujon P, Bezard E, Taupignon A, Bioulac B, Benazzouz A (2007) Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. J Neurosci 27:9595\u20139606","journal-title":"J Neurosci"},{"key":"242_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2007.06.025","volume":"54","author":"A Borgkvist","year":"2008","unstructured":"Borgkvist A, Marcellino D, Fuxe K, Greengard P, Fisone G (2008) Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol. Neuropharmacology 54:31\u201335","journal-title":"Neuropharmacology"},{"key":"242_CR6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/syn.10112","volume":"46","author":"J Bove","year":"2002","unstructured":"Bove J, Marin C, Bonastre M, Tolosa E (2002) Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. Synapse 46:251\u2013257","journal-title":"Synapse"},{"key":"242_CR7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bj\u00f6rklund A (2007) Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819\u20131833","journal-title":"Brain"},{"key":"242_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(98)00911-X","volume":"366","author":"M Casas","year":"1999","unstructured":"Casas M, Prat G, Robledo P, Barbanoj M, Kulisevsky J, Jan\u00e9 F (1999) Scopolamine prevents tolerance to the effects of caffeine on rotational behavior in 6-hydroxydopamine-denervated rats. Eur J Pharmacol 366:1\u201311","journal-title":"Eur J Pharmacol"},{"key":"242_CR9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00726-001-0116-4","volume":"23","author":"MA Cenci","year":"2002","unstructured":"Cenci MA (2002) Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease. Amino Acids 23:105\u2013109","journal-title":"Amino Acids"},{"key":"242_CR10","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","volume":"10","author":"MA Cenci","year":"1998","unstructured":"Cenci MA, Lee CS, Bj\u00f6rklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694\u20132706","journal-title":"Eur J Neurosci"},{"key":"242_CR11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.0953-816x.2001.01485.x","volume":"13","author":"D Centonze","year":"2001","unstructured":"Centonze D, Picconi B, Gubellini P, Bernardi G, Calabresi P (2001) Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur J Neurosci 13:1071\u20131077 (review)","journal-title":"Eur J Neurosci"},{"key":"242_CR12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.parkreldis.2004.02.012","volume":"10","author":"TN Chase","year":"2004","unstructured":"Chase TN (2004) Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism Relat Disord 10:305\u2013313 (review)","journal-title":"Parkinsonism Relat Disord"},{"key":"242_CR13","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1002\/1531-8249(200001)47:1<122::AID-ANA21>3.0.CO;2-9","volume":"47","author":"TN Chase","year":"2000","unstructured":"Chase TN, Oh JD (2000) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 47:S122\u2013S130","journal-title":"Ann Neurol"},{"key":"242_CR14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","volume":"22","author":"G Fabbrini","year":"2007","unstructured":"Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22:1379\u20131389","journal-title":"Mov Disord"},{"key":"242_CR15","doi-asserted-by":"crossref","first-page":"11940","DOI":"10.1073\/pnas.172393799","volume":"99","author":"S Ferr\u00e9","year":"2002","unstructured":"Ferr\u00e9 S, Karcz-Kubicha M, Hope BT, Popoli P, Burgue\u00f1o J, Guti\u00e9rrez MA, Casad\u00f3 V, Fuxe K, Goldberg SR, Lluis C, Franco R, Ciruela F (2002) Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci USA 99:11940\u201311945","journal-title":"Proc Natl Acad Sci USA"},{"key":"242_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0014-2999(95)00313-A","volume":"283","author":"F Fornai","year":"1995","unstructured":"Fornai F, Bassi L, Torracca MT, Scalori V, Corsini GU (1995) Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur J Pharmacol 283:99\u2013102","journal-title":"Eur J Pharmacol"},{"key":"242_CR17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/neur.1996.0032","volume":"5","author":"F Fornai","year":"1996","unstructured":"Fornai F, Bassi L, Torracca MT, Alessandri MG, Scalori V, Corsini GU (1996) Region- and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents. Neurodegeneration 5:241\u2013249","journal-title":"Neurodegeneration"},{"key":"242_CR18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1471-4159.1999.0720777.x","volume":"72","author":"F Fornai","year":"1999","unstructured":"Fornai F, Giorgi FS, Alessandri MG, Giusiani M, Corsini GU (1999) Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. J Neurochem 72:777\u2013784","journal-title":"J Neurochem"},{"key":"242_CR19","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2174\/092986707781745550","volume":"14","author":"F Fornai","year":"2007","unstructured":"Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A (2007) Noradrenaline in Parkinson\u2019s disease: from disease progression to current therapeutics. Curr Med Chem 14:2330\u20132334 (review)","journal-title":"Curr Med Chem"},{"key":"242_CR20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.1148","volume":"16","author":"SH Fox","year":"2001","unstructured":"Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16:642\u2013650","journal-title":"Mov Disord"},{"key":"242_CR40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0014-4886(91)90058-K","volume":"111","author":"JM Fritschy","year":"1991","unstructured":"Fritschy JM, Grzanna R (1991) Experimentally-induced neuron loss in the locus coeruleus of adult rats. Exp Neurol 111:123\u2013127","journal-title":"Exp Neurol"},{"key":"242_CR21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002109900167","volume":"361","author":"R Grondin","year":"2000","unstructured":"Grondin R, Hadj TA, Doan VD, Ladure P, Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves l-DOPA-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361:181\u2013186","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"242_CR22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1034\/j.1600-0773.2000.d01-35.x","volume":"86","author":"J Harro","year":"2000","unstructured":"Harro J, Merik\u00fcla A, Lepiku M, Modiri A-R, Rinken A, Oreland L (2000) Lesioning of locus coeruleus projections by DSP-4 neurotoxin treatment: effect on amphetamine-induced hyperlocomotion and dopamine D2 receptor binding in rats. Pharmacol Toxicol 86:197\u2013202","journal-title":"Pharmacol Toxicol"},{"key":"242_CR23","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archneur.63.12.1756","volume":"63","author":"RA Hauser","year":"2006","unstructured":"Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63:1756\u20131760","journal-title":"Arch Neurol"},{"key":"242_CR24","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22:2409\u20132417","journal-title":"Mov Disord"},{"key":"242_CR25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0306-4522(01)00509-7","volume":"109","author":"H Hermann","year":"2002","unstructured":"Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109:451\u2013460","journal-title":"Neuroscience"},{"key":"242_CR26","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0306-4522(99)00260-2","volume":"93","author":"M Holmberg","year":"1999","unstructured":"Holmberg M, Scheinin M, Kurose H, Miettinen R (1999) Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 93:1323\u20131333","journal-title":"Neuroscience"},{"key":"242_CR27","first-page":"19","volume":"45","author":"O Hornykiewicz","year":"1987","unstructured":"Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson\u2019s disease. Adv Neurol 45:19\u201334","journal-title":"Adv Neurol"},{"key":"242_CR28","first-page":"39","volume-title":"Parkinson\u2019s disease","author":"P Jenner","year":"2002","unstructured":"Jenner P (2002) Experimental models of Parkinson\u2019s disease. In: Ronken E, van Scharrenburg G (eds) Parkinson\u2019s disease. IOS Press, London, pp 39\u201350"},{"key":"242_CR29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.neuroscience.2004.12.032","volume":"132","author":"J Katz","year":"2005","unstructured":"Katz J, Nielsen KM, Soghomonian JJ (2005) Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits in the substantia nigra, pars reticulata. Neuroscience 132:833\u2013842","journal-title":"Neuroscience"},{"key":"242_CR30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nbd.2004.07.005","volume":"17","author":"C Konradi","year":"2004","unstructured":"Konradi C, Westin JE, Carta M, Eaton ME, Kuter K, Dekundy A, Lundblad M, Cenci MA (2004) Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia. Neurobiol Dis 17:219\u2013236","journal-title":"Neurobiol Dis"},{"key":"242_CR31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/ana.20102","volume":"55","author":"AE Lang","year":"2004","unstructured":"Lang AE, Obeso JA (2004) Time to move beyond nigrostriatal dopamine deficiency in Parkinson\u2019s disease. Ann Neurol 55:761\u2013765","journal-title":"Ann Neurol"},{"key":"242_CR32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1098-2396(20000615)36:4<267::AID-SYN3>3.0.CO;2-Y","volume":"36","author":"C Marin","year":"2000","unstructured":"Marin C, Jimenez A, Bonastre M, Chase TN, Tolosa E (2000) Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Synapse 36:267\u2013274","journal-title":"Synapse"},{"key":"242_CR33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0014-4886(03)00107-9","volume":"183","author":"C Marin","year":"2003","unstructured":"Marin C, Bove J, Bonastre M, Tolosa E (2003) Effect of acute and chronic administration of U50, 488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa. Exp Neurol 183:66\u201373","journal-title":"Exp Neurol"},{"key":"242_CR34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.expneurol.2004.10.008","volume":"192","author":"C Marin","year":"2005","unstructured":"Marin C, Aguilar E, Bonastre M, Tolosa E, Obeso JA (2005) Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp Neurol 192:184\u2013193","journal-title":"Exp Neurol"},{"key":"242_CR35","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00702-008-0060-5","volume":"115","author":"C Marin","year":"2008","unstructured":"Marin C, Aguilar E, Bonastre M (2008) Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats. J Neural Transm 115:1133\u20131139","journal-title":"J Neural Transm"},{"key":"242_CR36","doi-asserted-by":"crossref","unstructured":"Marin C, Aguilar E, Rodr\u00edguez-Oroz MC, Bartoszyk GD, Obeso JA (2009) Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology (Berl) [Epub ahead of print]","DOI":"10.1007\/s00213-008-1452-9"},{"key":"242_CR37","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1046\/j.1471-4159.1999.721516.x","volume":"72","author":"DW Miller","year":"1999","unstructured":"Miller DW, Abercrombie ED (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous l-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72:1516\u20131522","journal-title":"J Neurochem"},{"issue":"11 Suppl 2","key":"242_CR38","first-page":"11","volume":"39","author":"JA Obeso","year":"1989","unstructured":"Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM (1989) Motor complications associated with chronic levodopa therapy in Parkinson\u2019s disease. Neurology 39(11 Suppl 2):11\u201319 (review)","journal-title":"Neurology"},{"key":"242_CR39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","volume":"662","author":"SM Papa","year":"1994","unstructured":"Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 662:69\u201374","journal-title":"Brain Res"},{"key":"242_CR41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0197-0186(02)00091-8","volume":"42","author":"V P\u00e9rez","year":"2003","unstructured":"P\u00e9rez V, Unzeta M (2003) PF 9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57\/BL6 mice. Neurochem Int 42:221\u2013229","journal-title":"Neurochem Int"},{"key":"242_CR42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejphar.2007.08.024","volume":"576","author":"V P\u00e9rez","year":"2007","unstructured":"P\u00e9rez V, Sosti V, Rubio A, Barbanoj M, Rodr\u00edguez-\u00c1lvarez J, Kulisevsky J (2007) Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. Eur J Pharmacol 576:83\u201390","journal-title":"Eur J Pharmacol"},{"key":"242_CR43","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2007.10.001","volume":"29","author":"B Picconi","year":"2008","unstructured":"Picconi B, Paill\u00e9 V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Cenci A, Calabresi P (2008) l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 29:327\u2013335","journal-title":"Neurobiol Dis"},{"key":"242_CR44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0169-328X(94)90223-2","volume":"23","author":"M Pompeiano","year":"1994","unstructured":"Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23:163\u2013178","journal-title":"Brain Res Mol Brain Res"},{"key":"242_CR45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s007020070083","volume":"107","author":"G Prat","year":"2000","unstructured":"Prat G, P\u00e9rez V, Rubio A, Casas M, Unzeta M (2000) The novel type B MAO inhibitor PF9601N enhances the duration of l-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats. J Neural Transm 107:409\u2013417","journal-title":"J Neural Transm"},{"key":"242_CR46","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.neuropharm.2008.06.002","volume":"55","author":"C Rangel-Barajas","year":"2008","unstructured":"Rangel-Barajas C, Silva I, Garc\u00eda-Ram\u00edrez M, S\u00e1nchez-Lemus E, Floran L, Aceves J, Erlij D, Flor\u00e1n B (2008) 6-OHDA-induced hemiparkinsonism and chronic l-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat. Neuropharmacology 55:704\u2013711","journal-title":"Neuropharmacology"},{"key":"242_CR47","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","volume":"16","author":"O Rascol","year":"2001","unstructured":"Rascol O, Arnulf I, Peyro-Saint PH, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y (2001) Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson\u2019s disease. Mov Disord 16:708\u2013713","journal-title":"Mov Disord"},{"key":"242_CR48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bcp.2007.01.036","volume":"74","author":"KS Rommelfanger","year":"2007","unstructured":"Rommelfanger KS, Weinshenker D (2007) Norepinephrine: the redheaded stepchild of Parkinson\u2019s disease. Biochem Pharmacol 74:177\u2013190 (review)","journal-title":"Biochem Pharmacol"},{"key":"242_CR49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1476-5381.1976.tb08619.x","volume":"58","author":"SB Ross","year":"1976","unstructured":"Ross SB (1976) Long-term effects of N-2-chlorethyl-N-ethyl-2-bromobenzylamine HCl on noradrenergic neurones in the rat brain and heart. Br J Pharmacol 58:521\u2013527","journal-title":"Br J Pharmacol"},{"key":"242_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.10.059","volume":"1129","author":"B Sahin","year":"2007","unstructured":"Sahin B, Galdi S, Hendrick J, Greene RW, Snyder GL, Bibb JA (2007) Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling. Brain Res 1129:1\u201314","journal-title":"Brain Res"},{"key":"242_CR51","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","volume":"18","author":"JM Savola","year":"2003","unstructured":"Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease. Mov Disord 18:872\u2013883","journal-title":"Mov Disord"},{"key":"242_CR52","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ana.21204","volume":"62","author":"V Sossi","year":"2007","unstructured":"Sossi V, de la Fuente-Fern\u00e1ndez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ (2007) Dopamine transporter relation to dopamine turnover in Parkinson\u2019s disease: a positron emission tomography study. Ann Neurol 62:468\u2013474","journal-title":"Ann Neurol"},{"key":"242_CR53","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1046\/j.1460-9568.2003.02684.x","volume":"17","author":"J Srinivasan","year":"2003","unstructured":"Srinivasan J, Schmidt WJ (2003) Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. Eur J Neurosci 17:2586\u20132592","journal-title":"Eur J Neurosci"},{"key":"242_CR54","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbr.2003.08.016","volume":"151","author":"J Srinivasan","year":"2004","unstructured":"Srinivasan J, Schmidt XJ (2004) Behavioral and neurochemical effects of noradrenergic depletions with DSP-4 in 6-hydroxydopamine-induced rat model of Parkinson\u2019s disease. Behav Brain Res 151:191\u2013199","journal-title":"Behav Brain Res"},{"key":"242_CR55","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00702-004-0259-z","volume":"112","author":"J Srinivasan","year":"2005","unstructured":"Srinivasan J, Schmidt WJ (2005) Serotonergic influence on the potentiation of d-amphetamine and apomorphine-induced rotational behavior by the alpha(2)-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats. J Neural Transm 112:1223\u20131236","journal-title":"J Neural Transm"},{"key":"242_CR56","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0306-4522(97)00180-2","volume":"80","author":"P Svenningsson","year":"1997","unstructured":"Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, Fredholm BB (1997) Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 80:1171\u20131185","journal-title":"Neuroscience"},{"key":"242_CR57","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.61.11.1705","volume":"61","author":"S Thobois","year":"2004","unstructured":"Thobois S, Vingerhoets F, Fraix V, Xie-Brustolin J, Mollion H, Costes N, Mertens P, Benabid AL, Pollack P, Broussolle E (2004) Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol 61:1705\u20131709","journal-title":"Arch Neurol"},{"key":"242_CR58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","volume":"367","author":"U Ungerstedt","year":"1971","unstructured":"Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69\u201393","journal-title":"Acta Physiol Scand Suppl"},{"key":"242_CR59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","volume":"60","author":"C Zarow","year":"2003","unstructured":"Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337\u2013341","journal-title":"Arch Neurol"},{"key":"242_CR60","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0022-3565(24)38271-0","volume":"289","author":"W Zhang","year":"1999","unstructured":"Zhang W, Klimek V, Farley JT, Zhu MY, Ordway GA (1999) Alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J Pharmacol Exp Ther 289:1286\u20131292","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0242-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-009-0242-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0242-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T17:59:22Z","timestamp":1739123962000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-009-0242-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,26]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["242"],"URL":"https:\/\/doi.org\/10.1007\/s00702-009-0242-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,26]]}}}